Emerging therapeutic targets in diffuse large B-cell lymphoma

Current Treatment Options in Oncology

Volumn 13, Issue 1, 2012, Pages 82-101

  Janakiram, Murali ^a,b   Thirukonda, Venu K ^a,b   Sullivan, Matthew ^a   Petrich, Adam M ^c  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

By high dose therapy with autologous stem cell transplant (HDT ASCT); Chemoimmunotherapy; Diffuse Large B Cell Lymphoma (DLBCL); Multi agent cytotoxic chemotherapy; Non Hodgkin Lymphoma (NHL); Rituximab; Therapeutic targets

Indexed keywords

ARTICLE; LARGE CELL LYMPHOMA;

EID: 84857641773     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-011-0178-9     Document Type: Article

References (123)

1. A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma (A report of The Non-Hodgkin's Lymphoma Classification Project). Blood 1997;89(11): 3909-3918.
2. Cancer Facts & Figures 2011, American Cancer Society. 2011.
3. LI Gordon, et al. 1992 Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma N Engl J Med 327 19 1342 9 1383819 10.1056/NEJM199211053271903 1:STN:280:DyaK3s%2FisVOmuw%3D%3D
4. RI Fisher, et al. 1993 Comparison of a Standard Regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma N Engl J Med 328 14 1002 1006 7680764 10.1056/NEJM199304083281404 1:STN:280: DyaK3s7ps1Kmtg%3D%3D (Pubitemid 23095683)
5. B Coiffier, et al. 2002 CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346 4 235 42 11807147 10.1056/NEJMoa011795 1:CAS:528:DC%2BD38XmslGgsw%3D%3D (Pubitemid 34438862)
6. M Pfreundschuh, et al. 2006 CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group Lancet Oncol 7 5 379 91 16648042 10.1016/S1470-2045(06)70664-7 1:CAS:528:DC%2BD28XjvFWlsbw%3D
7. B Coiffier, et al. 2010 Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte Blood 116 12 2040 5 20548096 10.1182/blood-2010-03-276246 1:CAS:528:DC%2BC3cXht1KisbbI
8. T Philip, et al. 1995 Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma N Engl J Med 333 23 1540 1545 7477169 10.1056/NEJM199512073332305 1:STN:280:DyaK28%2FmslCgtQ%3D%3D
9. C Gisselbrecht, et al. 2010 Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era J Clin Oncol 28 27 4184 4190 20660832 10.1200/JCO.2010.28.1618
10. The International Non-Hodgkin's Lymphoma Prognostic Factors Project 1993 A predictive model for aggressive non-Hodgkin's lymphoma N Engl J Med 329 14 987 94 10.1056/NEJM199309303291402 (Pubitemid 23307906)
11. AA Alizadeh, et al. 2000 Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling Nature 403 6769 503 11 10676951 10.1038/35000501 1:CAS:528:DC%2BD3cXht1Shtrg%3D (Pubitemid 30082188)
12. G Lenz, et al. 2008 Stromal gene signatures in large-B-cell lymphomas N Engl J Med 359 22 2313 23 19038878 10.1056/NEJMoa0802885 1:CAS:528: DC%2BD1cXhsVehtbvF
13. S Monti, et al. 2005 Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response Blood 105 5 1851 61 15550490 10.1182/blood-2004-07-2947 1:CAS:528:DC%2BD2MXitVOnsrY%3D (Pubitemid 40731764)
14. A Rosenwald, et al. 2002 The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma N Engl J Med 346 25 1937 1947 12075054 10.1056/NEJMoa012914 (Pubitemid 34651353)
15. PJ Jost J Ruland 2007 Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications Blood 109 7 2700 7 17119127 1:CAS:528:DC%2BD2sXjvVygu7Y%3D (Pubitemid 46482061)
16. SB Gauld JM Dal Porto JC Cambier 2002 B cell antigen receptor signaling: roles in cell development and disease Science 296 5573 1641 2 12040177 10.1126/science.1071546 1:CAS:528:DC%2BD38XktlCht7o%3D (Pubitemid 34579149)
17. RE Davis, et al. 2010 Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma Nature 463 7277 88 92 20054396 10.1038/nature08638 1:CAS:528:DC%2BC3cXhvFCitw%3D%3D
18. G Lenz, et al. 2008 Oncogenic CARD11 mutations in human diffuse large B cell lymphoma Science 319 5870 1676 9 18323416 10.1126/science.1153629 1:CAS:528:DC%2BD1cXjsVamtbg%3D (Pubitemid 351432507)
19. SV Rajkumar, et al. 2005 Proteasome inhibition as a novel therapeutic target in human cancer J Clin Oncol 23 3 630 9 15659509 10.1200/JCO.2005.11.030 1:CAS:528:DC%2BD2MXitVartb0%3D (Pubitemid 46224241)
20. K Dunleavy, et al. 2009 Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma Blood 113 24 6069 76 19380866 10.1182/blood-2009-01-199679 1:CAS:528: DC%2BD1MXnslSmurs%3D In this study of relapsed/refractory disease, the addition of Bortezomib to DA-EPOCH yielded significantly better clinical outcomes in patients with ABC-like DLBCL, as compared to those with GCB- like DLBCL, providing strong clinical evidence that the NF-kβ pathway might be an important target in the treatment of ABC-DLBCL.
21. RR Furman, et al. 2010 Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma Cancer 116 23 5432 9 20665890 10.1002/cncr.25509 1:CAS:528:DC%2BC3cXhs1Wnur3N
22. J Ruan, et al. 2011 Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma J Clin Oncol: Official Journal of the American Society of Clinical Oncology 29 6 690 7 10.1200/JCO.2010.31.1142 1:CAS:528:DC%2BC3MXjvVSrsro%3D
23. NIH. www.clinicaltrials.gov. 2011.
24. V Kotla, et al. 2009 Mechanism of action of lenalidomide in hematological malignancies J Hematol Oncol 2 36 19674465 10.1186/1756-8722-2-36
25. N Mitsiades, et al. 2002 Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications Blood 99 12 4525 30 12036884 10.1182/blood.V99.12.4525 1:CAS:528: DC%2BD38XksFGksL4%3D (Pubitemid 34627223)
26. TE Witzig, et al. 2011 An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma Ann Oncol 22 7 1622 7 21228334 10.1093/annonc/mdq626 1:STN:280: DC%2BC3Mnjt1aqtQ%3D%3D
27. Zinzani PL, et al. Combination of Lenalidomide and Rituximab in Elderly Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 2 Trial. Clin Lymphoma Myeloma Leuk. 2011.
28. Nowakowski GS, et al. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia. 2011.
29. Hernandez-Ilizaliturri FJ, et al. Higher response to lenalidomide in relapsed/refractory diffuse large b-cell lymphoma in nongerminal center b-cell-like than in germinal center b-cell-like phenotype. Cancer 2011.
30. LA Honigberg, et al. 2010 The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy Proc Natl Acad Sci U S A 107 29 13075 80 20615965 10.1073/pnas.1004594107 1:CAS:528:DC%2BC3cXpsVCrsbk%3D
31. Advani R, Sharman J, Smith S. Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study. J Clin Oncol. 2010; 28:15s(suppl; abstr 8012).
32. JW Friedberg, et al. 2010 Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia Blood 115 13 2578 85 19965662 10.1182/blood-2009-08-236471 1:CAS:528:DC%2BC3cXksFOhs70%3D
33. MA Shipp, et al. 2002 Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning Nat Med 8 1 68 74 11786909 10.1038/nm0102-68 1:CAS:528:DC%2BD38XjtlygsQ%3D%3D (Pubitemid 34101731)
34. S Riihijarvi, et al. 2010 Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patients Mod Pathol 23 5 686 93 20190733 10.1038/modpathol.2010.43 1:CAS:528:DC%2BC3cXlsFSjt7w%3D
35. M Civallero, et al. 2011 Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma Expert Opin Investig Drugs 20 8 1029 31 21702717 10.1517/13543784.2011.594793 1:CAS:528:DC%2BC3MXoslOls7s%3D
36. MJ Robertson, et al. 2007 Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma J Clin Oncol 25 13 1741 6 17389337 10.1200/JCO.2006.09.3146 1:CAS:528:DC%2BD2sXlvFyktbg%3D (Pubitemid 46797955)
37. Hainsworth JD, Arrowsmith E, McCleod M, et al. Randomized phase II study of R-CHOP plus enzastaurin versus R-CHOP in the first-line treatment of patients with intermediate- and high-risk diffuse large B-cell lymphoma (DLBCL): Preliminary analysis. J Clin Oncol. 2011;29 suppl 8016.
38. Haioun C, Morschhauser F, Jourdan E, et al. Preliminary results of a phase II study of rituximab (R), gemcitabine (Gem), oxaliplatin (Ox) plus enzastaurin (ENZ) followed by ENZ maintenance as salvage regimen for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). J Clin Oncol. 2010;28(15, Suppl 8069).
39. WH Chappell, et al. 2011 Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health Oncotarget 2 3 135 64 21411864
40. X Zhou, et al. 2004 Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers Clin Cancer Res 10 20 6779 88 15501954 10.1158/1078-0432.CCR-04- 0112 1:CAS:528:DC%2BD2cXpslGlt7c%3D (Pubitemid 39383026)
41. O David, et al. 2004 Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage Clin Cancer Res 10 20 6865 71 15501963 10.1158/1078-0432.CCR-04-0174 1:CAS:528: DC%2BD2cXpslGltLY%3D (Pubitemid 39383035)
42. S Uddin, et al. 2006 Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival Blood 108 13 4178 86 16946303 10.1182/blood-2006-04-016907 1:CAS:528:DC%2BD28XhtlWqsrjK (Pubitemid 44913290)
43. C Vezina A Kudelski SN Sehgal 1975 Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle J Antibiot (Tokyo) 28 10 721 6 1:CAS:528: DyaE28Xis1eruw%3D%3D
44. J Heitman NR Movva MN Hall 1991 Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast Science 253 5022 905 9 1715094 10.1126/science.1715094 1:CAS:528:DyaK3MXlsl2hsr8%3D (Pubitemid 21917235)
45. BD Kahan 2000 Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group Lancet 356 9225 194 202 10963197 10.1016/S0140-6736(00)02480-6 1:CAS:528:DC%2BD3cXltVOgsL8%3D (Pubitemid 30446974)
46. G Hudes, et al. 2007 Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 22 2271 81 17538086 10.1056/NEJMoa066838 1:CAS:528:DC%2BD2sXmtVKkurs%3D (Pubitemid 46849157)
47. G Hess, et al. 2009 Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma J Clin Oncol 27 23 3822 9 19581539 10.1200/JCO.2008.20.7977 1:CAS:528:DC%2BD1MXhtFaitrrN
48. SM Smith, et al. 2010 Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium J Clin Oncol 28 31 4740 6 20837940 10.1200/JCO.2010.29.2813 1:CAS:528: DC%2BC3cXhsF2rtLzK The mTOR inhibitor Temsirolimus was shown to have clinically significant activity as a single agent in relapsed/refractory DLBCL, in a phase 2 study, prompting further evaluation of this class of medication, in combination with other agents, in NHL.
49. TE Witzig, et al. 2011 A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma Leukemia 25 2 341 7 21135857 10.1038/leu.2010.226 1:CAS:528:DC%2BC3MXhs1amsL4%3D
50. F Stauffer P Holzer C Garcia-Echeverria 2005 Blocking the PI3K/PKB pathway in tumor cells Curr Med Chem Anticancer Agents 5 5 449 62 16178772 10.2174/1568011054866937 1:CAS:528:DC%2BD2MXovV2rsrk%3D (Pubitemid 41166514)
51. BJ Lannutti, et al. 2011 CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability Blood 117 2 591 4 20959606 10.1182/blood-2010-03-275305 1:CAS:528:DC%2BC3MXht1aqtro%3D
52. SE Herman, et al. 2010 Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals Blood 116 12 2078 88 20522708 10.1182/blood-2010-02-271171 1:CAS:528:DC%2BC3cXht1KisbbF
53. Coutre SE, Byrd JC, Furman RR, et al. Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3'kinase P110d, in patients with previously treated chronic lymphocytic leukemia. J Clin Oncol. 2011;29 suppl; abstr 6631.
54. Kahl BS, Byrd J, MD2, Flinn IW, et al. Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma ASH Annual Meeting Abstracts 116, 1777, 2010
55. AP Bhatt, et al. 2010 Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas Blood 115 22 4455 63 20299510 10.1182/blood-2009-10-251082 1:CAS:528:DC%2BC3cXnsFKnt7c%3D
56. Tolcher AW, Y.T., Fearen I, et al. A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST). J Clin Oncol. 2009;36(15s, abstr 3503).
57. Petrich AM, Leshchenko V, Kuo P-Y, et al. Genomic and Pathway Connectivity Analyses Identify Novel Strategies to Overcome mTOR Inhibitor Resistance In DLBCL. ASH Annual Meeting, 2010.
58. Hendrickson AEW, Gupta M, Yun S, et al. OSI-027, a Dual TORC1/TORC2 Inhibitor, Induces Bim- and Puma-Mediated Apoptosis In Lymphoid Malignancy ASH Annual Meeting, 2010.
59. Gupta M, Hendrickson A, Han JJ, et al. Dual Inhibition of mTORC1/mTORC2 Induces Apoptosis of Mantle Cell Lymphoma by Preventing Rictor Mediated AKTS473 Phosphorylation by Potentiating AKT2-PHLPP1 Association. Ash Annual Meeting, 2010.
60. Tan DS, Dumez H, Olmos D, et al. First-in-human phase I study exploring three schedules of OSI-027, a novel small molecule TORC1/TORC2 inhibitor, in patients with advanced solid tumors and lymphoma. J Clin Oncol. 2010;28(15s; abstr 3006).
61. Brana I, LoRusso P, Baselga J. A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies. J Clin Oncol. 2010;28(15s; abstr 3030).
62. Y Tsujimoto, et al. 1984 Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation Science 226 4678 1097 9 6093263 10.1126/science.6093263 1:CAS:528:DyaL2MXhvVyjug%3D%3D (Pubitemid 15217831)
63. BH Ye, et al. 1993 Cloning of bcl-6, the locus involved in chromosome translocations affecting band 3q27 in B-cell lymphoma Cancer Res 53 12 2732 5 8504412 1:CAS:528:DyaK3sXltlKmtLk%3D (Pubitemid 23180506)
64. MH Kang CP Reynolds 2009 Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy Clin Cancer Res 15 4 1126 32 19228717 10.1158/1078-0432.CCR-08-0144 1:CAS:528:DC%2BD1MXitVOksLg%3D
65. JC Reed M Pellecchia 2005 Apoptosis-based therapies for hematologic malignancies Blood 106 2 408 18 15797997 10.1182/blood-2004-07-2761 1:CAS:528:DC%2BD2MXmtleqsL8%3D (Pubitemid 40981231)
66. BF Skinnider, et al. 1999 Bcl-6 and Bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: correlation with 3q27 and 18q21 chromosomal abnormalities Hum Pathol 30 7 803 8 10414499 10.1016/S0046-8177(99) 90141-7 1:CAS:528:DyaK1MXkvFejtb0%3D (Pubitemid 29325787)
67. SJ Korsmeyer 1992 Bcl-2 initiates a new category of oncogenes: regulators of cell death Blood 80 4 879 86 1498330 1:CAS:528:DyaK3sXnvVShsQ%3D%3D
68. AL Shaffer A Rosenwald LM Staudt 2002 Lymphoid malignancies: the dark side of B-cell differentiation. Nature reviews Immunology 2 12 920 32 12461565 1:CAS:528:DC%2BD38XptFKnu7s%3D (Pubitemid 37323213)
69. JN Winter, et al. 2006 Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study Blood 107 11 4207 13 16449523 10.1182/blood-2005-10-4222 1:CAS:528: DC%2BD28Xlt1CgsrY%3D (Pubitemid 43801342)
70. J Iqbal, et al. 2006 BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma J Clin Oncol 24 6 961 8 16418494 10.1200/JCO.2005.03.4264 1:CAS:528:DC%2BD28Xitl2qt7s%3D (Pubitemid 46638851)
71. JS Waters, et al. 2000 Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma J Clin Oncol 18 9 1812 23 10784621 1:CAS:528:DC%2BD3cXjvVensbo%3D (Pubitemid 30261918)
72. B Pro, et al. 2008 Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma Br J Haematol 143 3 355 60 18764869 10.1111/j.1365-2141.2008.07353.x 1:CAS:528:DC%2BD1cXhsVeqsLvO
73. Kingsley E, Richards D, Garbo L, et al. An open-label, multicenter, phase II study of AT-101 in combination with rituximab (R) in patients with untreated, grade 1-2, follicular non-Hodgkin's lymphoma (FL). J Clin Oncol. 2009;27(15 s, abstr 8582).
74. JJ Hwang, et al. 2010 Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma Clin Cancer Res 16 15 4038 45 20538761 10.1158/1078-0432.CCR-10-0822 1:CAS:528:DC%2BC3cXpsVCit7Y%3D
75. JW Huang, et al. 2008 Fragment-based design of small molecule X-linked inhibitor of apoptosis protein inhibitors J Med Chem 51 22 7111 8 18956862 10.1021/jm8006992 1:CAS:528:DC%2BD1cXhtlWqtb7O
76. WH Wilson, et al. 2010 Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity Lancet Oncol 11 12 1149 59 21094089 10.1016/S1470-2045(10)70261-8 1:CAS:528:DC%2BC3cXhsVyhsLbN
77. K Basso R Dalla-Favera 2010 BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis Adv Immunol 105 193 210 20510734 10.1016/S0065-2776(10)05007-8 1:CAS:528:DC%2BC3cXhtFSnurfJ
78. LM Staudt, et al. 1999 Regulation of lymphocyte cell fate decisions and lymphomagenesis by BCL-6 Int Rev Immunol 18 4 381 403 10626250 10.3109/08830189909088490 1:CAS:528:DyaK1MXlvVGgsrw%3D (Pubitemid 29392083)
79. G Cattoretti, et al. 2005 Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice Cancer Cell 7 5 445 55 15894265 10.1016/j.ccr.2005.03.037 1:CAS:528:DC%2BD2MXkslyitLw%3D (Pubitemid 40719128)
80. MP Butler, et al. 2002 Alternative translocation breakpoint cluster region 5′ to BCL-6 in B-cell non-Hodgkin's lymphoma Cancer Res 62 14 4089 94 12124346 1:CAS:528:DC%2BD38XlsV2lsbk%3D (Pubitemid 34791079)
81. LC Cerchietti, et al. 2009 A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo Blood 113 15 3397 405 18927431 10.1182/blood-2008-07-168773 1:CAS:528:DC%2BD1MXkslCkurw%3D
82. LC Cerchietti, et al. 2010 A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo Cancer Cell 17 4 400 11 20385364 10.1016/j.ccr.2009.12.050 1:CAS:528:DC%2BC3cXmsF2msb8%3D
83. LC Cerchietti, et al. 2009 A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas Nat Med 15 12 1369 76 19966776 10.1038/nm.2059 1:CAS:528:DC%2BD1MXhsFWksb3N
84. P Feugier, et al. 2005 Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte J Clin Oncol 23 18 4117 26 15867204 10.1200/JCO.2005.09.131 1:CAS:528:DC%2BD2MXmt1elsr0%3D (Pubitemid 46211317)
85. A Martin, et al. 2008 R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study Haematologica 93 12 1829 36 18945747 10.3324/haematol.13440 1:CAS:528:DC%2BD1MXhtFyntb0%3D
86. T Robak E Robak 2011 New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies BioDrugs 25 1 13 25 21090841 10.2165/11539590-000000000-00000 1:CAS:528:DC%2BC3MXjt12gs78%3D
87. in Arzerra (ofatumumab) Prescribing Information. GlaxoSmithKline; Research Triangle Park, NC2010.
88. JL Teeling, et al. 2006 The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20 J Immunol 177 1 362 71 16785532 1:CAS:528:DC%2BD28XlvV2nt74%3D (Pubitemid 43939148)
89. Coiffier B, Bosly A, Wu KL, et al. Ofatumumab Monotherapy for Treatment of Patients with Relapsed/Progressive Diffuse Large B-Cell Lymphoma: Results From a Multicenter Phase II Study ASH Annual Meeting. 2010. Poster Board III-734.
90. R Stein, et al. 2004 Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma Clin Cancer Res 10 8 2868 78 15102696 10.1158/1078-0432.CCR-03-0493 1:CAS:528:DC%2BD2cXjt1Clurs%3D (Pubitemid 38509167)
91. F Morschhauser, et al. 2009 Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results J Clin Oncol 27 20 3346 53 19451441 10.1200/JCO.2008.19.9117 1:CAS:528:DC%2BD1MXpvFejt7g%3D
92. B Coiffier, et al. 1998 Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study Blood 92 6 1927 32 9731049 1:CAS:528: DyaK1cXmtVOhtbs%3D (Pubitemid 28446681)
93. F Kausar, et al. 2009 Ocrelizumab: a step forward in the evolution of B-cell therapy Expert Opin Biol Ther 9 7 889 95 19463076 10.1517/ 14712590903018837 1:CAS:528:DC%2BD1MXnt1Shs7s%3D
94. F Morschhauser, et al. 2010 Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma Ann Oncol 21 9 1870 6 20157180 10.1093/annonc/mdq027 1:STN:280:DC%2BC3cjmtlektg%3D%3D
95. E Mossner, et al. 2010 Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity Blood 115 22 4393 402 20194898 10.1182/blood-2009-06-225979 1:CAS:528:DC%2BC3cXnsFKnt7w%3D
96. Cartron G, TC, Solal-Celigny P, et al. Promising Efficacy with the New Anti-CD20 Antibody GA101 In Heavily Pre-Treated NHL Patients - First Results From a Phase II Study In Patients with Relapsed/Refractory DLBCL and MCL. ASH Annual Meeting, Board II-758, 2010.
97. J Carnahan, et al. 2007 Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab Mol Immunol 44 6 1331 41 16814387 10.1016/j.molimm.2006.05.007 1:CAS:528:DC%2BD28XpvVOgtr4%3D (Pubitemid 44415959)
98. Micallef IN, et al. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma. Blood 2011.
99. D Nagorsen PA Baeuerle 2011 Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab Exp Cell Res 317 9 1255 60 21419116 10.1016/j.yexcr.2011.03.010 1:CAS:528:DC%2BC3MXlvVyjt70%3D
100. Viardot A, Goebeler M, Scheele J, et al. Treatment of Patients With Non-Hodgkin Lymphoma With CD19/CD3 Bispecific Antibody Blinatumomab (MT103): Double-Step Dose Increase to Continuous Infusion of 60 μg/m2/day is Tolerable and Highly Effective.. Blood, 2010;116(21, ASH Abstract # 2880).
101. PA Marks VM Richon RA Rifkind 2000 Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells J Natl Canc Ins 92 15 1210 1216 10.1093/jnci/92.15.1210 1:CAS:528:DC%2BD3cXlvFyhsb8%3D (Pubitemid 30627729)
102. C Van Lint S Emiliani E Verdin 1996 The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation Gene expression 5 4-5 245 53 8723390
103. RL Piekarz SE Bates 2009 Epigenetic modifiers: basic understanding and clinical development Clin Canc Res: An official journal of the American Association for Cancer Research 15 12 3918 26 10.1158/1078-0432.CCR-08-2788 1:CAS:528:DC%2BD1MXntlOisrk%3D
104. EA Olsen, et al. 2007 Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma J Clin Oncol: Official journal of the American Society of Clinical Oncology 25 21 3109 15 10.1200/JCO.2006.10.2434 1:CAS:528:DC%2BD2sXptlGrtrs%3D (Pubitemid 47218059)
105. RL Piekarz, et al. 2009 Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma J Clin Oncology: Official journal of the American Society of Clinical Oncology 27 32 5410 7 10.1200/JCO.2008.21.6150 1:CAS:528: DC%2BD1MXhsFKkt7vO
106. Coiffier B, Pro B, Prince HM, et al. Final results from a pivotal, multicenter, international, open-label, phase 2 study of Romidepsin In Progressive or Relapsed Peripheral T-Cell Lymphoma (PTCL) Following Prior Systemic Therapy. ASH Annual Meeting Oral Session 2010.
107. WK Kelly, et al. 2005 Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer J Clin Oncol: Official journal of the American Society of Clinical Oncology 23 17 3923 31 10.1200/JCO.2005.14.167 1:CAS:528:DC%2BD2MXmtVahtLw%3D (Pubitemid 46218695)
108. M Crump, et al. 2008 Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma Ann Oncol: Official journal of the European Society for Medical Oncology/ESMO 19 5 964 9 10.1093/annonc/mdn031 1:STN:280:DC%2BD1c3nvFelsQ%3D%3D (Pubitemid 351627315)
109. S Bhalla, et al. 2009 PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells Clin Canc Res: An official journal of the American Association for Cancer Research 15 10 3354 65 10.1158/1078-0432.CCR-08-2365 1:CAS:528:DC%2BD1MXmtVKmurc%3D
110. G Dasmahapatra, et al. 2010 The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo Blood 115 22 4478 4487 20233973 10.1182/blood-2009-12-257261 1:CAS:528:DC%2BC3cXnsFKntLw%3D
111. Y Dai, et al. 2008 Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells Clin Canc Res: An official journal of the American Association for Cancer Research 14 2 549 58 10.1158/1078-0432.CCR-07-1934 1:CAS:528:DC%2BD1cXhtVKhsLc%3D (Pubitemid 351226125)
112. L Catley, et al. 2006 Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells Blood 108 10 3441 9 16728695 10.1182/blood-2006-04-016055 1:CAS:528:DC%2BD28Xht1ahsLzM
113. P Gimsing, et al. 2008 A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia Eur J Haematol 81 3 170 6 18510700 10.1111/j.1600-0609.2008.01102.x 1:CAS:528:DC%2BD1cXhtFentLzK
114. J Goffin 2002 DNA methyltransferase inhibitors-state of the art Ann Oncol 13 11 1699 1716 12419742 10.1093/annonc/mdf314 1:STN:280:DC%2BD38nlvFaisA%3D%3D (Pubitemid 35439450)
115. PA Jones PW Laird 1999 Cancer epigenetics comes of age Nat Genet 21 2 163 7 9988266 10.1038/5947 1:CAS:528:DyaK1MXpsVClug%3D%3D (Pubitemid 29070360)
116. SB Baylin JG Herman 2000 DNA hypermethylation in tumorigenesis: epigenetics joins genetics Trends Genet 16 4 168 174 10729832 10.1016/S0168-9525(99)01971-X 1:CAS:528:DC%2BD3cXit1Sqsbg%3D (Pubitemid 30169152)
117. JG Herman, et al. 1995 Inactivation of the CDKN2/p16/MTS1 Gene is frequently associated with aberrant DNA methylation in all common human cancers Cancer Res 55 20 4525 4530 7553621 1:CAS:528:DyaK2MXoslWmsrk%3D
118. Al-Ali HK, et al. Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study. Leuk Lymphoma 2011.
119. DJ Stewart, et al. 2009 Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas Clin Canc Res: An official journal of the American Association for Cancer Research 15 11 3881 8 10.1158/1078-0432.CCR-08-2196 1:CAS:528: DC%2BD1MXmsFOju7g%3D
120. KA Blum, et al. 2010 Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation Br J Haematol 150 2 189 95 20456354 1:CAS:528:DC%2BC3cXhtVegsLzL
121. S Shaker M Bernstein RL Momparler 2004 Antineoplastic action of 5-aza-2′-deoxycytidine (Dacogen) and depsipeptide on Raji lymphoma cells Oncol Rep 11 6 1253 6 15138563 1:CAS:528:DC%2BD2cXkvVWht74%3D
122. Kalac M, et al. HDAC inhibitors and decitabine are highly synergistic and associated with unique gene expression and epigenetic profiles in models of DLBCL. Blood 2011.
123. A Stathis, et al. 2011 Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas Clin Canc Res: An official journal of the American Association for Cancer Research 17 6 1582 90 10.1158/1078-0432.CCR-10-1893 1:CAS:528: DC%2BC3MXjtFChtrs%3D